Ketamine in Palliative and End-of-Life Care

Ketamine's Role at the End of Life

End-of-life care faces two distinct but intertwined challenges: physical pain and existential suffering. Advanced cancer, organ failure, and progressive neurological conditions produce pain that frequently escapes control with standard opioid regimens, and the existential distress of facing death — anxiety, depression, loss of meaning, fear — profoundly diminishes quality of life in the final months or years.

Ketamine addresses both challenges through different but complementary mechanisms. For broader context on ketamine's pain management role, see our article on troches for chronic pain, making it an increasingly valued tool in palliative care settings and, in limited forms, in hospice.

Pain Management in Palliative Care

Opioid-Refractory Pain

Advanced cancer and other terminal conditions produce pain through multiple mechanisms — nociceptive, neuropathic, and central sensitization components are often all present simultaneously. As disease progresses, opioid requirements escalate, and opioid-induced hyperalgesia may paradoxically worsen pain.

Ketamine's NMDA receptor blockade addresses:

• Central sensitization: The amplified pain processing that develops with chronic, severe pain (the dosage for pain article covers specific protocols)
• Neuropathic components: Nerve pain, which responds poorly to opioids but often responds to NMDA antagonists
• Opioid-induced hyperalgesia (OIH): Ketamine can reverse OIH and potentially allow opioid dose reduction with improved pain control

Clinical Evidence in Palliative Pain

Multiple palliative care organizations and clinical trials have examined ketamine for refractory pain in advanced illness:

• Studies show meaningful pain reduction in 50 to 70 percent of patients with opioid-refractory cancer pain
• Addition of ketamine to opioid regimens can reduce total opioid requirements while improving pain control
• Neuropathic cancer pain — one of the most difficult pain types — shows particular responsiveness to ketamine

Dosing for Palliative Pain

Palliative pain ketamine often involves continuous low-dose infusions in inpatient settings, but oral and sublingual formulations have a role for ambulatory palliative patients:

• Low-dose oral/sublingual: 50 to 150 mg ketamine, 1 to 3 times daily for analgesic maintenance
• This sub-dissociative range provides meaningful analgesia without impairing daily function
• As patients become less mobile or transition to hospice, the route may shift to continuous subcutaneous infusion

Existential Distress and End-of-Life Depression

The Burden of Existential Suffering

Beyond physical pain, patients facing terminal illness often experience profound psychological and existential distress:

• Depression: Affects 25 to 40 percent of patients with advanced cancer
• Anxiety: Pervasive fear of dying, physical suffering, loss of control
• Demoralization: Hopelessness, meaninglessness, loss of sense of self
• Existential regret: Unresolved relationships, unfinished business, grief
• Death anxiety: Fear of nonexistence, the dying process, what comes after

These experiences significantly impair quality of life and quality of dying. Standard treatments (antidepressants, anxiolytics) work too slowly for many palliative patients with limited prognosis.

Ketamine for End-of-Life Psychological Distress

Ketamine's rapid-acting antidepressant, anxiolytic, and experientially transformative effects have attracted attention in the palliative care context. The dissociative experience at therapeutic doses — the ego softening, the reduction in fear-based self-focus, the potential for profound shifts in perspective — has led to its study as a means of addressing existential distress.

Similarities to Psychedelic Therapy

Research on psilocybin-assisted therapy for end-of-life existential distress (Johns Hopkins and NYU trials) has demonstrated that the mystical-type experiences produced by psilocybin reduce death anxiety and depression significantly and durably. Ketamine's dissociative experience shares some qualities with psychedelic experiences — ego dissolution, sense of expanded perspective, reduction in attachment to ordinary self — though it is distinct pharmacologically.

Several case reports and small studies suggest that ketamine sessions produce reductions in existential distress, death anxiety, and demoralization in terminal patients. The evidence base is small but conceptually coherent.

Practical Troche Use in Palliative Care

Who Uses Ketamine Troches in Palliative Settings?

Ambulatory patients with advanced illness who:

• Have maintained adequate swallowing and oral absorption
• Are experiencing either refractory pain or significant depression/existential distress
• Are being managed by a palliative care specialist familiar with ketamine
• Have weeks to months of life expectancy (sufficient time to benefit from the treatment)

Protocol Considerations

Palliative care ketamine often combines low-dose analgesic dosing with periodic higher-dose sessions for psychological work:

Low-dose analgesic troches: 50 to 100 mg, daily or as needed for breakthrough pain relief. These can be incorporated into the broader analgesic regimen.

Moderate-dose session troches: 150 to 250 mg, once every 1 to 4 weeks, for existential distress and antidepressant effects. These sessions are ideally accompanied by skilled psychological support.

Adjusting for Prognosis

As prognosis shortens and functional status declines, the goals and format of ketamine use shift:

• Early in palliative care: Establishing ketamine as part of a multimodal pain and psychological management plan
• As disease progresses: Simplifying regimens; transitioning from complex troche schedules to simpler dosing
• In the final weeks: Ketamine may transition to continuous subcutaneous infusion or may be discontinued in favor of palliative sedation approaches

Family and Support System Considerations

For patients using ketamine in a home palliative care context, family members and caregivers need to be:

• Informed about what a ketamine session involves
• Prepared to provide calm support during sessions
• Trained in basic safety monitoring (ensuring the patient remains in a safe position)
• Connected to the palliative care team for questions and concerns

Compassionate Use and Ethical Considerations

Dignity and Autonomy

Ketamine's ability to produce experiences of expanded perspective, reduced fear, and moments of profound calm or even transcendence holds particular value when framed through the lens of dying with dignity. Patients who have access to meaningful psychological experiences in their final months may approach death with greater equanimity.

The compassionate use of ketamine in end-of-life care — including potential for spiritually or existentially meaningful experiences — is an ethically defensible and increasingly recognized dimension of holistic palliative care.

Addiction Risk in Palliative Context

In the context of terminal illness, the usual concerns about long-term dependence and addiction potential are largely moot. Quality of life in the time remaining takes precedence over long-term medication safety considerations that apply to patients with normal life expectancy.

Provider Scope and Training

Not all palliative care providers are familiar with or comfortable prescribing ketamine. Patients interested in this option should seek providers with experience in both palliative care and ketamine prescribing. Palliative care organizations are increasingly producing educational resources on ketamine, reflecting growing acceptance of its role.

Key Takeaways

• Ketamine addresses both refractory pain and existential/psychological distress in end-of-life care.
• Low-dose analgesic troches (50 to 100 mg) provide pain relief for opioid-refractory palliative pain.
• Moderate-dose sessions address depression, death anxiety, and demoralization with rapid effect.
• In terminal illness, long-term safety concerns about ketamine are less relevant; quality of remaining life takes priority.
• Palliative ketamine requires providers experienced in both areas; access is growing as awareness increases.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches